{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T03:07:50Z","timestamp":1792638470309,"version":"4.5.0"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.semarthrit.2024.152426","type":"journal-article","created":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T04:03:00Z","timestamp":1709265780000},"page":"152426","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["Treatment with Janus kinase inhibitors in juvenile dermatomyositis: A review of the literature"],"prefix":"10.1016","volume":"66","author":[{"given":"Seher","family":"Sener","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veysel","family":"Cam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seza","family":"Ozen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1065-2363","authenticated-orcid":false,"given":"Ezgi Deniz","family":"Batu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.semarthrit.2024.152426_bib0001","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s12969-017-0174-0","article-title":"Biologic therapies for refractory juvenile dermatomyositis: Five years of experience of the childhood arthritis and rheumatology research alliance in north america","volume":"15","author":"Spencer","year":"2017","journal-title":"Pediatr Rheumatol Online J"},{"issue":"2","key":"10.1016\/j.semarthrit.2024.152426_bib0002","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1136\/annrheumdis-2016-209247","article-title":"Consensus-based recommendations for the management of juvenile dermatomyositis","volume":"76","author":"Bellutti Enders","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1016\/j.semarthrit.2024.152426_bib0003","doi-asserted-by":"crossref","first-page":"4154","DOI":"10.4049\/jimmunol.168.8.4154","article-title":"Gene expression profiling in DQA1\u00d70501+ children with untreated dermatomyositis: A novel model of pathogenesis","volume":"168","author":"Tezak","year":"2002","journal-title":"J Immunol"},{"issue":"1","key":"10.1016\/j.semarthrit.2024.152426_bib0004","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1186\/s12969-021-00637-8","article-title":"JAK inhibitors: A potential treatment for JDM in the context of the role of interferon-driven pathology","volume":"19","author":"Ll Wilkinson","year":"2021","journal-title":"Pediatr Rheumatol Online J"},{"key":"10.1016\/j.semarthrit.2024.152426_bib0005","article-title":"Compassionate Use Treatment Protocol I4V-MC-JAGA: Treatment of conditions expected to benefit From JAK 1\/2 Inhibition: CANDLE, CANDLE-Related Conditions","author":"Lilly","year":"2023","journal-title":"SAVI and Severe Juvenile Dermatomyositis"},{"key":"10.1016\/j.semarthrit.2024.152426_bib0006","unstructured":"Gitiaux C. Baricitinib in the Treatment of New-onset Juvenile Dermatomyositis (MYOCIT) (MYOCIT). https:\/\/clinicaltrials.gov\/study\/NCT05524311?cond=Juvenile%20Dermatomyositis&intr=Baricitinib&rank=1 (accessed January 09, 2024)."},{"issue":"11","key":"10.1016\/j.semarthrit.2024.152426_bib0007","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1007\/s00296-011-1999-3","article-title":"Writing a narrative biomedical review: Considerations for authors, peer reviewers, and editors","volume":"31","author":"Gasparyan","year":"2011","journal-title":"Rheumatol Int"},{"issue":"11","key":"10.1016\/j.semarthrit.2024.152426_bib0008","doi-asserted-by":"crossref","first-page":"e80","DOI":"10.1093\/brain\/awy255","article-title":"A child with severe juvenile dermatomyositis treated with ruxolitinib","volume":"141","author":"Aeschlimann","year":"2018","journal-title":"Brain"},{"issue":"12","key":"10.1016\/j.semarthrit.2024.152426_bib0009","doi-asserted-by":"crossref","first-page":"e15960","DOI":"10.1111\/dth.15960","article-title":"Juvenile dermatomyositis-associated calcinosis successfully treated with combined immunosuppressive, bisphosphonate, oral baricitinib and physical therapy","volume":"35","author":"Agud-Dios","year":"2022","journal-title":"Dermatol Ther"},{"issue":"2","key":"10.1016\/j.semarthrit.2024.152426_bib0010","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1111\/1756-185X.14258","article-title":"Janus kinase inhibition in induction treatment of anti-MDA5 juvenile dermatomyositis-associated rapidly progressive interstitial lung disease","volume":"25","author":"Chan Ng","year":"2022","journal-title":"Int J Rheum Dis"},{"issue":"4","key":"10.1016\/j.semarthrit.2024.152426_bib0011","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1136\/annrheumdis-2020-218582","article-title":"Janus kinase inhibitor significantly improved rash and muscle strength in juvenile dermatomyositis","volume":"80","author":"Ding","year":"2021","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.semarthrit.2024.152426_bib0012","doi-asserted-by":"crossref","first-page":"e136","DOI":"10.1093\/rheumatology\/keaa657","article-title":"Interferon signature guiding therapeutic decision making: Ruxolitinib as first-line therapy for severe juvenile dermatomyositis?","volume":"60","author":"Heinen","year":"2021","journal-title":"Rheumatol (Oxford)"},{"issue":"3","key":"10.1016\/j.semarthrit.2024.152426_bib0013","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1093\/rheumatology\/keac399","article-title":"Long-term follow-up of Janus-kinase inhibitor and novel active disease biomarker in juvenile dermatomyositis","volume":"62","author":"Huang","year":"2023","journal-title":"Rheumatol (Oxford)"},{"issue":"8","key":"10.1016\/j.semarthrit.2024.152426_bib0014","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1111\/1756-185X.14630","article-title":"Cardiac involvement in a case of juvenile dermatomyositis with positive anti-melanoma differentiation associated protein 5 antibody","volume":"26","author":"Kaplan","year":"2023","journal-title":"Int J Rheum Dis"},{"issue":"3","key":"10.1016\/j.semarthrit.2024.152426_bib0015","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1136\/annrheumdis-2020-218690","article-title":"Janus kinase (JAK) inhibition with baricitinib in refractory juvenile dermatomyositis","volume":"80","author":"Kim","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2024.152426_bib0016","doi-asserted-by":"crossref","DOI":"10.3389\/fped.2022.820586","article-title":"The safety and efficacy of tofacitinib in 24 cases of pediatric rheumatic diseases: Single centre experience","volume":"10","author":"Kostik","year":"2022","journal-title":"Front Pediatr"},{"issue":"1","key":"10.1016\/j.semarthrit.2024.152426_bib0017","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s12969-022-00690-x","article-title":"Nodular Regenerative Hyperplasia of the liver in Juvenile Dermatomyositis","volume":"20","author":"Lanis","year":"2022","journal-title":"Pediatr Rheumatol Online J"},{"issue":"12","key":"10.1016\/j.semarthrit.2024.152426_bib0018","doi-asserted-by":"crossref","first-page":"5801","DOI":"10.1093\/rheumatology\/keab116","article-title":"JAK inhibitors are effective in a subset of patients with juvenile dermatomyositis: A monocentric retrospective study","volume":"60","author":"Le Voyer","year":"2021","journal-title":"Rheumatol (Oxford)"},{"issue":"2","key":"10.1016\/j.semarthrit.2024.152426_bib0019","first-page":"402","article-title":"Efficacy of Janus kinase inhibitor baricitinib in the treatment of refractory juvenile dermatomyositis complicated by calcinosis","volume":"41","author":"Mastrolia","year":"2023","journal-title":"Clin Exp Rheumatol"},{"issue":"8","key":"10.1016\/j.semarthrit.2024.152426_bib0020","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1093\/rheumatology\/kez525","article-title":"Anti-MDA5 juvenile idiopathic inflammatory myopathy: A specific subgroup defined by differentially enhanced interferon-\u03b1 signalling","volume":"59","author":"Melki","year":"2020","journal-title":"Rheumatol (Oxford)"},{"issue":"3","key":"10.1016\/j.semarthrit.2024.152426_bib0021","doi-asserted-by":"crossref","first-page":"e8","DOI":"10.1093\/brain\/awz005","article-title":"Janus kinase 1\/2 inhibition with baricitinib in the treatment of juvenile dermatomyositis","volume":"142","author":"Papadopoulou","year":"2019","journal-title":"Brain"},{"issue":"1","key":"10.1016\/j.semarthrit.2024.152426_bib0022","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1080\/24725625.2020.1832755","article-title":"Fatal outcome of anti-MDA5 juvenile dermatomyositis in a paediatric COVID-19 patient: A case report","volume":"5","author":"Quintana-Ortega","year":"2021","journal-title":"Mod Rheumatol Case Rep"},{"issue":"1","key":"10.1016\/j.semarthrit.2024.152426_bib0023","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s10875-021-01119-y","article-title":"Onset and relapse of juvenile dermatomyositis following asymptomatic SARS-CoV-2 infection","volume":"42","author":"Rodero","year":"2022","journal-title":"J Clin Immunol"},{"issue":"11","key":"10.1016\/j.semarthrit.2024.152426_bib0024","doi-asserted-by":"crossref","first-page":"e59","DOI":"10.1093\/brain\/awz293","article-title":"Treatment of anti-MDA5 autoantibody-positive juvenile dermatomyositis using tofacitinib","volume":"142","author":"Sabbagh","year":"2019","journal-title":"Brain"},{"issue":"12","key":"10.1016\/j.semarthrit.2024.152426_bib0025","doi-asserted-by":"crossref","first-page":"e140","DOI":"10.1093\/rheumatology\/keaa360","article-title":"A striking treatment option for recalcitrant calcinosis in juvenile dermatomyositis: Tofacitinib citrate","volume":"59","author":"S\u00f6zeri","year":"2020","journal-title":"Rheumatol (Oxford)"},{"issue":"1","key":"10.1016\/j.semarthrit.2024.152426_bib0026","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s12969-022-00675-w","article-title":"Progressive, refractory macrophage activation syndrome as the initial presentation of anti-MDA5 antibody positive juvenile dermatomyositis: A case report and literature review","volume":"20","author":"Stewart","year":"2022","journal-title":"Pediatr Rheumatol Online J"},{"issue":"8S","key":"10.1016\/j.semarthrit.2024.152426_bib0027","doi-asserted-by":"crossref","first-page":"S777","DOI":"10.1097\/RHU.0000000000001489","article-title":"Juvenile Dermatomyositis: A Rare But Treatable Cause of Acute Myocardial Dysfunction","volume":"27","author":"Vaiyani","year":"2021","journal-title":"J Clin Rheumatol"},{"issue":"2","key":"10.1016\/j.semarthrit.2024.152426_bib0028","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.medcli.2021.03.022","article-title":"Refractory juvenile dermatomyositis: Response to tofacitinib","volume":"158","author":"Zhou","year":"2022","journal-title":"Med Clin (Barc)"},{"issue":"11","key":"10.1016\/j.semarthrit.2024.152426_bib0029","doi-asserted-by":"crossref","first-page":"3579","DOI":"10.12998\/wjcc.v10.i11.3579","article-title":"Anti-nuclear matrix protein 2+ juvenile dermatomyositis with severe skin ulcer and infection: A case report and literature review","volume":"10","author":"Wang","year":"2022","journal-title":"World J Clin Cases"},{"key":"10.1016\/j.semarthrit.2024.152426_bib0030","article-title":"Short-term effectiveness of baricitinib in children with refractory and\/or severe juvenile dermatomyositis","volume":"10","author":"Wang","year":"2022","journal-title":"Front Pediatr"},{"issue":"11","key":"10.1016\/j.semarthrit.2024.152426_bib0031","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1136\/ard-2023-223919","article-title":"Efficiency of tofacitinib in refractory interstitial lung disease among anti-MDA5 positive juvenile dermatomyositis patients","volume":"82","author":"Xue","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1016\/j.semarthrit.2024.152426_bib0032","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2022-252592","article-title":"Cyclophosphamide-induced liver injury during treatment of interstitial lung disease in juvenile dermatomyositis","volume":"16","author":"Zhang","year":"2023","journal-title":"BMJ Case Rep"},{"issue":"4","key":"10.1016\/j.semarthrit.2024.152426_bib0033","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1093\/rheumatology\/keaa558","article-title":"Successful management with Janus kinase inhibitor tofacitinib in refractory juvenile dermatomyositis: A pilot study and literature review","volume":"60","author":"Yu","year":"2021","journal-title":"Rheumatol (Oxford)"},{"issue":"6","key":"10.1016\/j.semarthrit.2024.152426_bib0034","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1002\/art.24555","article-title":"Elevated serum interferon-alpha activity in juvenile dermatomyositis: Associations with disease activity at diagnosis and after thirty-six months of therapy","volume":"60","author":"Niewold","year":"2009","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.semarthrit.2024.152426_bib0035","doi-asserted-by":"crossref","first-page":"7140","DOI":"10.1038\/s41598-022-10777-w","article-title":"Adverse events associated with JAK inhibitors in 126,815 reports from the WHO pharmacovigilance database","volume":"12","author":"Hoisnard","year":"2022","journal-title":"Sci Rep"},{"issue":"3","key":"10.1016\/j.semarthrit.2024.152426_bib0036","doi-asserted-by":"crossref","first-page":"e14939","DOI":"10.1111\/dth.14939","article-title":"JAK-inhibitors for dermatomyositis: A concise literature review","volume":"34","author":"Paudyal","year":"2021","journal-title":"Dermatol Ther"},{"issue":"2","key":"10.1016\/j.semarthrit.2024.152426_bib0037","first-page":"348","article-title":"Use of Janus kinase inhibitors in dermatomyositis: A systematic literature review","volume":"41","author":"Paik","year":"2023","journal-title":"Clin Exp Rheumatol"},{"issue":"2","key":"10.1016\/j.semarthrit.2024.152426_bib0038","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1186\/ar4198","article-title":"Adult and juvenile dermatomyositis: Are the distinct clinical features explained by our current understanding of serological subgroups and pathogenic mechanisms?","volume":"15","author":"Tansley","year":"2013","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.semarthrit.2024.152426_bib0039","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1186\/1471-2474-14-298","article-title":"Efficacy and safety of tofacitinib in the treatment of rheumatoid arthritis: A systematic review and meta-analysis","volume":"14","author":"He","year":"2013","journal-title":"BMC Musculoskelet Disord"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017224000660?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017224000660?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,15]],"date-time":"2024-06-15T01:47:06Z","timestamp":1718416026000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017224000660"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":39,"alternative-id":["S0049017224000660"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2024.152426","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment with Janus kinase inhibitors in juvenile dermatomyositis: A review of the literature","name":"articletitle","label":"Article Title"},{"value":"Seminars in Arthritis and Rheumatism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semarthrit.2024.152426","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"152426"}}